This study reveals the critical role of F7 in immune evasion in gastric cancer, providing a direct theoretical basis and experimental direction for designing targeted therapeutic strategies combined with PD-L1 blockade.
Literature Overview
This article, titled "F7 Drives Gastric Cancer Metastasis Through Anoikis Resistance and Tumor Microenvironment Remodeling," published in Advanced Science, systematically explores the molecular mechanisms of Coagulation Factor VII (F7) in gastric cancer metastasis and immune microenvironment remodeling. The study not only elucidates how F7 promotes tumor cell anoikis resistance by activating the ITGA2 signaling pathway via an autocrine loop, but also reveals its dual immune evasion mechanism: upregulating PD-L1 expression and promoting Collagen I deposition to inhibit CD8+ T cell infiltration. Furthermore, the study successfully screened Thonningianin A (THA), a small-molecule inhibitor capable of blocking this pathway.Background Knowledge
Gastric cancer is a highly lethal malignancy worldwide, with poor prognosis primarily attributed to early metastasis and the immunosuppressive nature of the tumor microenvironment (TME). Although PD-1/PD-L1 immune checkpoint inhibitors are currently used clinically, their response rates remain limited, and there is a lack of combined strategies targeting the synergistic effects of intrinsic tumor plasticity and microenvironment remodeling. As a key factor in the coagulation cascade, the tumor biological role of F7 in non-coagulation functions has long been overlooked. Specifically in gastric cancer, its expression regulatory network, downstream signaling axes, and mechanisms driving resistance to anoikis remain unclear. Moreover, how to block F7-mediated ITGA2 signaling and reverse the immunosuppression caused by high PD-L1 expression represents a major bottleneck in the field of tumor immunotherapy. This study, spanning from transcriptional regulation (HNF4A) to protein-protein interactions (F7-ITGA2) and small-molecule intervention, offers a novel entry point for overcoming gastric cancer metastasis and immune resistance.
Research Methods and Core Experiments
The authors first utilized the TCGA database and a clinical cohort (including 214 patient samples) to analyze the expression profile of F7 in gastric cancer and its correlation with lymph node metastasis, prognosis, and CD8+ T cell infiltration. To verify function, the study constructed F7-knockdown and F7-overexpressing gastric cancer cell lines (e.g., MKN45, HGC27) and simulated anoikis conditions (suspension culture) in vitro, combining Transwell and scratch assays to evaluate cell migration and invasion capabilities. In vivo, the team established a mouse liver metastasis model (spleen injection) and a lymph node metastasis model (footpad injection), using bioluminescence imaging and pathological staining (TUNEL, LYVE-1) to quantitatively assess metastatic burden. For mechanistic analysis, Immunoprecipitation-Mass Spectrometry (IP-MS) was employed to identify the F7-interacting protein ITGA2, and truncation mutants combined with molecular docking techniques precisely mapped the binding sites (the K1.2/K1.3 regions of F7 and the N-terminus of ITGA2). Additionally, ChIP-qPCR and dual-luciferase reporter assays confirmed the direct regulatory role of the transcription factor HNF4A on the F7 promoter. Finally, virtual screening, Surface Plasmon Resonance (SPR), and Cellular Thermal Shift Assay (CETSA) were used to screen and validate the target binding capability and anti-tumor activity of the small-molecule inhibitor THA.Key Conclusions and Perspectives
Research Significance and Prospects
This discovery provides a highly promising new target, F7, for gastric cancer drug development, particularly for late-stage gastric cancer patients who are resistant to immune checkpoint inhibitors. By blocking the F7-ITGA2 axis, tumor metastasis can be inhibited while simultaneously remodeling the tumor microenvironment to relieve PD-L1-mediated immunosuppression, offering robust preclinical evidence for combination therapeutic strategies. Furthermore, the HNF4A-F7 regulatory axis revealed in this study offers a new perspective on transcriptional reprogramming under anoikis stress, aiding in the development of disease modeling and precision intervention tools for specific stress states. Future research should further explore the safety of THA in clinical translation and its synergistic effects with other immunotherapies.
Conclusion
This study provides an in-depth analysis of the multifaceted mechanisms by which F7 acts as a driver of gastric cancer metastasis, constructing a comprehensive molecular map ranging from transcriptional regulation and protein interactions to microenvironment remodeling. The research not only confirms the central role of F7 in mediating anoikis resistance and immune evasion but also successfully identifies the THA small-molecule inhibitor with significant translational potential. This achievement marks a leap in gastric cancer drug development from single-target blockade to a dual strategy of "anti-metastasis + immune sensitization." Clinically, detecting F7 expression levels may serve as an important biomarker for predicting prognosis and immunotherapy response in gastric cancer patients. The combination of F7 inhibitors with PD-1/PD-L1 antibodies holds promise to break through the current bottlenecks in late-stage gastric cancer treatment, significantly improving patient survival benefits. This study lays a crucial scientific foundation for establishing a more precise care system for related diseases, accelerating the translation process from laboratory discovery to clinical application.
